摘要 |
The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers. |
主权项 |
1. An antibody that binds human Ang2 (SEQ ID NO: 7), comprising a light chain (LC) and a heavy chain (HC), wherein the light chain comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences KASQDVYIAVA (SEQ ID NO: 8), YWASTRDT (SEQ ID NO: 9), and HQYSSYPPT (SEQ ID NO: 10), respectively, and wherein the heavy chain comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 consisting of the amino acid sequences GYSFTDYNMV (SEQ ID NO: 11), YIDPYNGGTGYNQKFEG (SEQ ID NO: 12), and ARTRDRYDVWYFDV (SEQ ID NO: 13), respectively. |